At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 14 Jul 1998 No-Development-Reported for Hypertension in USA (Unknown route)
- 15 Dec 1995 Preclinical development for Hypertension in USA (Unknown route)
- 06 Apr 1995 New profile